Codexis ( (CDXS) ) has provided an announcement.
On April 9, 2025, Codexis announced that Byron Dorgan will retire from its Board of Directors at the end of his current term during the 2025 Annual Meeting of Stockholders. Dorgan, who joined the board in 2011 and served as Chairman from 2021 to 2024, will continue as a consultant for a year post-retirement. His departure will reduce the board’s size from ten to nine members. The announcement highlights Dorgan’s contributions to Codexis’s transformation into a leading therapeutics manufacturing company and his pride in the company’s progress, particularly with the ECO Synthesis platform.
Spark’s Take on CDXS Stock
According to Spark, TipRanks’ AI Analyst, CDXS is a Neutral.
Codexis faces significant financial challenges, with declining revenues and persistent losses weighing heavily on its stock score. Technical analysis suggests bearish trends with limited upside momentum. While future guidance from the earnings call and strategic board changes offer some optimism, the stock remains risky due to valuation concerns and operational inefficiencies.
To see Spark’s full report on CDXS stock, click here.
More about Codexis
Codexis is a leading provider of enzymatic solutions for efficient and scalable therapeutics manufacturing, utilizing its proprietary CodeEvolver technology platform to develop high-performance enzymes. These enzymes address challenges in small molecule pharmaceuticals manufacturing and nucleic acid synthesis, and the company is advancing its ECO Synthesis platform for RNAi therapeutics manufacturing.
YTD Price Performance: -60.60%
Average Trading Volume: 914,346
Technical Sentiment Signal: Strong Buy
Current Market Cap: $170.2M
See more data about CDXS stock on TipRanks’ Stock Analysis page.